Biotechnology entrepreneur. Founder and CEO of NovaBiotics. Immunologist designing and developing much needed novel antimicrobial strategies for over 20 years.
Not only did the ‘driver’ ensure a 2 min silence either side of 1100, but I’m sure he dipped a wing at 1100 (not checking in case that was just a headwind coincidence…) Well done #Loganair
That's one week down of Curious 2023 - but there's still loads to come...
We've had a fantastic first week delving under the surface - from forensic science to primate research and everything in between!
Don't miss out on our exciting programme & visit https://t.co/dk5U8dMWPd
Leaders, pioneers, icons ✨👑
Join us for this event as we bring four of these world-leading scientists from the exhibition to the stage to share their inspirations and journeys through their STEM careers.
https://t.co/iim3XWdv9Y
Community Acquired Pneumonia (CAP) is an unmet global health & socioeconomic issue. Prevalence is increasing and a challenging winter CAP season driven by COVID, influenza & bacterial infections looms. Read more about NM002, our immunomodulator-antimicrobial candidate therapy 👇
Are you a singing scientist or healthcare professional?
We need your help!! We’re recruiting our chorus for @edfringe. Auditions 14th & 21st of May in Edinburgh. Apply now at https://t.co/oGdgfw9xwK
Community Acquired Pneumonia (CAP) remains a significant cause of morbidity & mortality. At #eccmid@dougfp78 will present new data on NM002, our immunomodulatory-antimicrobial candidate in phase 3 clinical development for CAP.
Posters L0185, April 24th & L0476, April 25th
The #EU Pharma Legislation revision is on the horizon. What solutions do #SMEs need from our policymakers to unlock the innovation potential to tackle #AMR? Check out this video and don’t hesitate to spread the voice of SMEs too: like, share, and comment! https://t.co/h4SSOHkcWB
Today is the 5th #WorldAspergillosisDay, raising awareness of the diseases & complications of existing conditions #Aspergillus causes. Our novel antifungal peptide NP339 is being developed for invasive & respiratory Aspergillus infections.
#thinkfungus#drugdiscovery#immunology
📣 Apply now for the #ONELifeSciences Boot Camp & Accelerator 👇
🌟 Test & develop your #lifesciences business concept
🌟 Create a compelling commercial proposition
🌟 Access up to £10k grant funding for your next steps
https://t.co/ljrf1M7oJY
#startup#Aberdeen#NEERSF
Don't miss @dougfp78 presenting new data in Poster #431 on 'Anti-virulence activities of cysteamine and protection from Pseudomonas toxicity in a Galleria mellonella model'
NACFC today at 1.10pm EST or 5.10pm GMT
#NACFC21#CysticFibrosis#Antimicrobials#drugdiscovery2021
Our latest publication, drilling further down into the mechanism of NM001 against Pseudomonas aeruginosa, still a major, poorly served driver of pathology in #cysticfibrosis. NM001 has potential in #CF, but also in other respiratory disease & against other bacterial pathogens👇👇
Very pleased to share further mechanistic insights highlighting the potential of our NM001 therapy candidate for #cysticfibrosis. Our latest publication is now out in a special Pseudomonas aeruginosa focused edition of @FrontiersIn https://t.co/Ifwy6FsCCv
@EOY_UK @NovaBiotics An absolute pleasure to be back on the UK panel & looking forward very much to spending time with this years’ amazing finalists & my esteemed judging teammates.